Myasthenia Gravis Clinical Trial
Official title:
A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Symptomatic Autoimmune Generalized Myasthenia Gravis
The purpose of this study is to determine whether the drug Leukine (GM-CFS) is safe and tolerated by patients with autoimmune myasthenia gravis (MG).
Twelve patients aged 18-80 with symptomatic generalized autoimmune MG that are not being treated with medication that suppresses their immune system, other than prednisone, will enter the study at UIC over a two year period. The study will involve a screening visit and visits at baseline and at days 5, 15, 30, 45, 60, 90, and 120. The study drug, Leukine (GM-CFS), is given by injection. Subjects will give themselves one dose of GM-CSF every day for 10 days. Study visits will include muscle testing, immunologic studies and quality-of-life studies. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05039190 -
Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
|
Phase 3 | |
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT01727193 -
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
|
Phase 3 | |
| Completed |
NCT00285350 -
Mycophenolate Mofetil in Myasthenia Gravis
|
Phase 3 | |
| Recruiting |
NCT05890833 -
The Risk of Falls Index for Patients With Neuromuscular Disorders
|
||
| Completed |
NCT05694234 -
Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
|
||
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Not yet recruiting |
NCT04965987 -
Oxaloacetate in Myasthenia Gravis
|
Phase 1 | |
| Not yet recruiting |
NCT05095103 -
Immune Profiles in Myasthenia Gravis
|
||
| Terminated |
NCT02102594 -
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
|
Phase 2 | |
| Completed |
NCT02066519 -
Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
|
N/A | |
| Completed |
NCT02774239 -
A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)
|
Phase 3 | |
| Completed |
NCT02118805 -
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
|
||
| Terminated |
NCT01828294 -
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
|
Phase 1 | |
| Terminated |
NCT00727194 -
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
|
Phase 2 | |
| Completed |
NCT04590716 -
Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
|
||
| Recruiting |
NCT04837625 -
Study of Myasthenic Crisis in China
|
||
| Not yet recruiting |
NCT01469858 -
Perception and Multisensory Integration in Neurological Patients Using fMRI
|
N/A | |
| Completed |
NCT05408702 -
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
|
||
| Completed |
NCT03205306 -
Myasthenia Gravis and Psyche
|